CytoMed Therapeutics’ (GDTC) Speculative Buy Rating Reaffirmed at Benchmark

CytoMed Therapeutics (NASDAQ:GDTCGet Free Report)‘s stock had its “speculative buy” rating reaffirmed by research analysts at Benchmark in a research note issued on Tuesday, Benzinga reports. They currently have a $5.00 target price on the stock. Benchmark’s target price would suggest a potential upside of 150.04% from the stock’s previous close.

CytoMed Therapeutics Trading Up 2.5 %

Shares of GDTC stock opened at $2.00 on Tuesday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 14.09 and a current ratio of 14.09. The company has a 50 day moving average price of $2.09 and a 200 day moving average price of $2.82. CytoMed Therapeutics has a fifty-two week low of $1.92 and a fifty-two week high of $9.25.

About CytoMed Therapeutics

(Get Free Report)

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers in Malaysia and Singapore. Its lead product candidate is CTM-N2D, which is in Phase I clinical trials comprising expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity.

Recommended Stories

Receive News & Ratings for CytoMed Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoMed Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.